To the content
4 . 2021

A clinical case of using gliclazide MR in a patient with type 2 diabetes mellitus

Abstract

Despite the variety of new antihyperglycemic drugs, the choice of effective and safe type 2 diabetes mellitus therapy remains an extremely important issue. In a pandemic of new coronavirus infection, adequate glycemic control is essential for a favorable outcome of the disease. A clinical case of the use of modified release gliclazide (gliclazide MR) as a second-line drug in combination with metformin, as well as an example of intensification of therapy based on therapy with gliclazide MR during the development of a new coronavirus infection is presented.

Keywords:type 2 diabetes mellitus, gliclazide MR, metformin, COVID-19, dipeptidyl peptidase-4 inhibitors, therapy, hypoglycemia, efficacy

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Kononenko I.V., Smirnova O.M. A clinical case of using gliclazide MR in a patient with type 2 diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (4): 79-86. DOI: https://doi.org/10.33029/2304-9529-2021-10-4-79-86 (in Russian)

REFERENCES

1. Standards of specialized diabetes care. In: I.I. Dedov., M.V. Shestakova, A. Yu. Mayorov (eds). 10th ed. Moscow, 2021. (in Russian)

2. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.A., Isakov M.A. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Sakharniy diabet [Diabetes Mellitus]. 2018; 21 (3): 144-59. DOI: https://doi.org/10.14341/DM9686 (in Russian)

3. Bode B., Garrett V., Messler J., et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020; 14 (4): 813-21. DOI: https://doi.org/10.1177/1932296820924469

4. DeFronzo R.A., Eldor R., Abdul-Ghani M. Pathophysiologic approach to therapy in T2DM. Diabetes Care. 2013; 36 (Suppl 2): S 127-38. DOI: https://doi.org/10.2337/dcS13-2011

5. Dedov I.I., Smirnova O.M., Kononenko I.V. New concepts of glucose-induced insulin secretion in the development of type 2 diabetes: clinical implications. Sakharniy diabet [Diabetes Mellitus]. 2015; 18 (3): 23-31. DOI: https://doi.org/10.14341/DM2015323-31 (in Russian)

6. Yasuda K., Inagaki N., Yamada Y., et al. Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells: its structure and functional properties. Biochem Biophys Res Commun. 1994; 205 (3): 1556-62. DOI: https://doi.org/10.1006/bbrc.1994.2844

7. Zaccardi F., Jacquot E., Cortese V., Tyrer F., Seidu S., Davies M.J., et al. Comparative effectiveness of gliclazide modified release versus sita-gliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2020; 22 (12): 2417-26. DOI: https://doi.org/10.1111/dom.14169

8. Maloney A., Rosenstock J., Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019; 105 (5): 1213-23.

9. Al Sifri S., Basiounny A., Echtay A., Al Omari M., et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with si-tagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011; 65: 1132-40.

10. Hassanein M., Al Sifri S., Shaikh S., Abbas Raza S., Akram J., Pranoto A., et al.; on behalf of the DIA-RAMADAN Study Investigators, A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract. 2020; 163: 108154. DOI: https://doi.org/10.1016/j.diabres.2020.108154

11. Schernthaner G., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004; 34: 535-42.

12. Matthews D.R. ADVANCE. Diabetes Obes Metab. 2020; 22 (Suppl 2): 3-4. DOI: https://doi.org/10.1111/dom.14014

13. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia. 2001; 44: 1118-20.

14. Zhou F., Yu T., Du R., Fan G., Liu Y., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10 229): 1054-62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3 Epub 2020 Mar 11.

15. Shestakova M.V., Vikulova O.K., Isakov M.A., Dedov I.I. Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the Russian diabetes registry. Problemy endokrinologii [Problems of Endocrinology]. 2020; 66 (1): 35-46. DOI: https://doi.org/10.14341/probl12458 (in Russian)

16. Drucker D.J. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020; 41: 457-70.

17. Hahn K., Ejaz A.A., Kanbay M., Lanaspa M.A. Johnson R.J. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016; 12: 711-2.

18. Stoian A.P., Papanas N., Prazny M., Rizvi A.A., Rizzo M. Incretin-based therapies role in COVID-19 era: evolving insights. J Car-diovasc Pharmacol Ther. 2020; 25 (6): 494-6. DOI: https://doi.org/10.1177/1074248420937868

19. Nauck M.A., Meier J.J. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019; 181: R 211-34.

20. Lukito A.A., Pranata R., Henrina J., Lim M.A., Lawrensia S., Suas-tika K. The Effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020; 14 (6): 2177-83. DOI: https://doi.org/10.1016/j.dsx.2020.11.006 Epub 2020 Nov 11. PMID: 33395778; PMCID: PMC 7657016.

21. Zhao W., Yu S., Zha X., Wang N., Pang Q., Li D., et al. Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study. medRxiv. 2020. DOI: https://doi.org/10.1101/2020.03.13.20035436

22. Luo M., Zuo Y., Guo J., Wen X., Kang Y. Continuous glucose monitoring system can improve the quality of glucose control and glucose variability compared with point-of-care measurement in critically ill patients: a randomized controlled trial. Medicine (Baltimore). 2018; 97: e12138.

23. Takahashi T., Shibasaki T., Takahashi H., et al. Antidiabetic sulfonyl-ureas and cAMP cooperatively activate Epac2A. Sci Signal. 2013; 6 (298): ra 94. DOI: https://doi.org/10.1126/scisignal.2004581

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»